{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-088054","form_type":"8-K","ticker":"HRGN","cik":"0001563665","company_name":"Harvard Apparatus Regenerative Technology, Inc.","filed_at":"2022-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.170929+00:00","generated_at":"2026-06-24T01:24:37.259380+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Biostage appoints Joseph Damasio as CFO; $250K salary, 116K-share option grant","bullets":["Mr. Damasio appointed CFO effective August 8, 2022; brings capital raising and biotech finance experience.","Initial annual base salary of $250,000, plus $25,000 bonus for remainder of FY2022 subject to milestones.","Granted nonqualified stock option for 116,156 shares vesting equally over four years.","Company intends to relist on NASDAQ and start clinical trial for esophageal implant.","Interim CEO David Green highlights Damasio's skills for operational management and capital raises."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-088054","json":"https://secwatch.observer/filing/0001104659-22-088054.json","markdown":"https://secwatch.observer/filing/0001104659-22-088054.md","text":"https://secwatch.observer/filing/0001104659-22-088054.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563665/000110465922088054/0001104659-22-088054-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563665/000110465922088054/tm2222955d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T01:24:37.259380+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"67453274e5","claim":"Joseph L. Damasio, Jr. was appointed as Chief Financial Officer at Harvard Apparatus Regenerative Technology, Inc..","evidence_excerpt":"Effective as of August 8, 2022, Biostage, Inc. (the Company) appointed Joseph L. Damasio, Jr., as Chief Financial Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1563665/000110465922088054/0001104659-22-088054-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}